当前位置:首页 - 行情中心 - 前沿生物-U(688221) - 财务分析 - 利润表

前沿生物-U

(688221)

  

流通市值:38.43亿  总市值:38.43亿
流通股本:3.75亿   总股本:3.75亿

利润表

报告期2025-03-312024-12-312024-09-302024-06-30
公司类型通用通用通用通用
一、营业总收入28,328,182.53129,472,935.9891,643,894.3951,056,036.51
营业收入28,328,182.53129,472,935.9891,643,894.3951,056,036.51
二、营业总成本74,909,155.77405,686,029.6282,018,728.06185,196,329.54
营业成本19,130,499.8785,546,537.9160,953,794.6735,377,390.3
税金及附加775,150.964,597,169.43,633,349.392,319,054.67
销售费用21,243,275.0686,344,001.8447,921,544.6634,124,281.19
管理费用17,144,817.3384,816,363.2452,388,599.6236,453,249.64
研发费用16,803,233.38137,205,648.06109,341,964.2972,701,164.58
财务费用-187,820.837,176,309.157,779,475.434,221,189.16
其中:利息费用2,363,345.9310,271,685.77,916,503.875,151,960.74
其中:利息收入2,804,501.344,120,130.851,801,887.66969,740.01
加:公允价值变动收益-206,446.4183,505.51991,376.04849,425.97
加:投资收益461,621.7184,091,885.0611,638,399.528,015,258.96
资产处置收益15,353.9318,798.6418,798.6418,798.64
资产减值损失(新)-152,429.13-46,727,551.35-41,141,862.41-41,556,725.57
信用减值损失(新)-897,500.57253,226.64-1,470,354.38-77,112.91
其他收益3,224,253.2837,399,668.227,143,391.836,681,337.78
营业利润平衡项目0000
四、营业利润-44,136,120.43-201,093,560.92-193,195,084.43-160,209,310.16
加:营业外收入16,187.6722,845.6620,499.134,150.44
减:营业外支出1,584.65311,895.13283,168.87253,918.43
利润总额平衡项目0000
五、利润总额-44,121,517.41-201,382,610.39-193,457,754.17-160,459,078.15
六、净利润-44,121,517.41-201,382,610.39-193,457,754.17-160,459,078.15
持续经营净利润-44,121,517.41-201,382,610.39-193,457,754.17-160,459,078.15
归属于母公司股东的净利润-44,121,517.41-201,382,610.39-193,457,754.17-160,459,078.15
(一)基本每股收益-0.12-0.54-0.52-0.43
(二)稀释每股收益-0.12-0.54-0.52-0.43
八、其他综合收益21,559.4611,919.84-9,917.824,068
归属于母公司股东的其他综合收益21,559.4611,919.84-9,917.824,068
九、综合收益总额-44,099,957.95-201,370,690.55-193,467,671.99-160,455,010.15
归属于母公司股东的综合收益总额-44,099,957.95-201,370,690.55-193,467,671.99-160,455,010.15
公告日期2025-04-302025-04-302024-10-312024-08-31
审计意见(境内)标准无保留意见
TOP↑